Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

$57.29 +0.25 (+0.44%)

As of 02:53 PM Eastern

Bristol-Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 21 Analyst Ratings

Sell
2

Hold
13

Buy
6

Based on 21 Wall Street analysts who have issued ratings for Bristol-Myers Squibb in the last 12 months, the stock has a consensus rating of "Hold." Out of the 21 analysts, 2 have given a sell rating, 13 have given a hold rating, 4 have given a buy rating, and 2 have given a strong buy rating for BMY.

Consensus Price Target

$56.27
-1.79% Downside

According to the 21 analysts' twelve-month price targets for Bristol-Myers Squibb, the average price target is $56.27. The highest price target for BMY is $73.00, while the lowest price target for BMY is $39.00. The average price target represents a forecasted downside of -1.79% from the current price of $57.29.

Get the Latest News and Ratings for BMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bristol-Myers Squibb and its competitors.

BMY Analyst Ratings Over Time

Type	Current Forecast 1/23/24 to 1/22/25	1 Month Ago 12/24/23 to 12/23/24	3 Months Ago 10/25/23 to 10/24/24	1 Year Ago 1/23/23 to 1/23/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	3 Buy rating(s)	1 Buy rating(s)	3 Buy rating(s)
Hold	13 Hold rating(s)	13 Hold rating(s)	14 Hold rating(s)	14 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$56.27	$55.64	$53.20	$62.41
Forecasted Upside	-1.79% Downside	-3.36% Downside	0.53% Upside	24.55% Upside
Consensus Rating	Hold	Hold	Reduce	Hold

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bristol-Myers Squibb Stock vs. The Competition

Type	Bristol-Myers Squibb	Medical Companies	S&P 500
Consensus Rating Score	2.29	2.82	2.52
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-1.06% Downside	25,046.27% Upside	11.51% Upside
News Sentiment Rating	Positive News See Recent BMY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/8/2025	Truist Financial 2 of 5 stars		Boost Target	Buy ➝ Buy	$62.00 ➝ $65.00	+13.60%
12/16/2024	Jefferies Financial Group 2 of 5 stars		Upgrade	Hold ➝ Buy	$63.00 ➝ $70.00	+25.49%
12/10/2024	Bank of America 3 of 5 stars		Reiterated Rating	Neutral	$63.00	+7.25%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
11/13/2024	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Nakagiri Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
11/13/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform
11/12/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
11/12/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$55.00 ➝ $60.00	+0.79%
11/12/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$57.00 ➝ $61.00	+2.09%
11/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underweight ➝ Underweight	$36.00 ➝ $39.00	-34.80%
Get the Latest News and Ratings for BMY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.
11/12/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$55.00 ➝ $73.00	+22.03%
10/18/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$50.00 ➝ $50.00	-5.98%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$56.00	+4.93%
10/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$50.00 ➝ $54.00	+2.27%
10/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Gould Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Underweight ➝ Underweight	$42.00 ➝ $43.00	-20.25%
10/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$53.00 ➝ $59.00	+9.32%
7/23/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$53.00 ➝ $45.00	+5.36%
4/18/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$51.00 ➝ $52.00	+8.11%
4/1/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Phipps Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/11/2024	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/6/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$77.00 ➝ $54.00	+12.50%
10/30/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$81.00 ➝ $69.00	+35.48%
10/27/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$55.00 ➝ $53.00	+0.03%
7/28/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$90.00 ➝ $85.00	+39.89%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$72.00 ➝ $66.00	+5.13%
7/10/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$66.00	+5.35%
4/28/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:53 PM ET.

Should I Buy Bristol-Myers Squibb Stock? BMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, January 14, 2025. Please send any questions or comments about these Bristol-Myers Squibb pros and cons to contact@marketbeat.com.

Bristol-Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers, such as Opdivo and Yervoy, which are well-regarded in the oncology market.
The company has demonstrated a commitment to innovation, with ongoing research and development in areas like immunology and hematology, potentially leading to new product launches that could drive revenue growth.
As of now, the stock price is approximately $55.62, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
Recent insider trading activity shows confidence in the company's future, with executives acquiring shares, indicating their belief in the company's growth potential.
Bristol-Myers Squibb's diverse product offerings across multiple therapeutic areas reduce reliance on any single product, providing a buffer against market volatility.

Bristol-Myers Squibb
Bear Case

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

The recent sale of shares by a senior vice president, which resulted in a 5.62% decrease in their position, may raise concerns about insider sentiment regarding the company's short-term performance.
With only 0.09% of the stock owned by insiders, there may be a lack of alignment between management and shareholder interests, which can be a red flag for potential investors.
In a competitive pharmaceutical landscape, Bristol-Myers Squibb faces challenges from generic drugs and other companies developing similar therapies, which could impact market share and profitability.
Regulatory hurdles and the lengthy approval process for new drugs can delay potential revenue streams, affecting the company's financial outlook.
Market fluctuations and economic uncertainties can impact the overall performance of pharmaceutical stocks, including Bristol-Myers Squibb, making it a riskier investment in volatile times.

BMY Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol-Myers Squibb is $56.27, with a high forecast of $73.00 and a low forecast of $39.00.
: 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 2 sell ratings, 13 hold ratings, 4 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.
: According to analysts, Bristol-Myers Squibb's stock has a predicted downside of -1.79% based on their 12-month stock forecasts.
: Over the previous 90 days, Bristol-Myers Squibb's stock had 5 upgrades and 1 downgrade by analysts.
: Bristol-Myers Squibb has been rated by research analysts at Bank of America, BMO Capital Markets, Citigroup, Daiwa America, Daiwa Capital Markets, Jefferies Financial Group, Leerink Partners, Leerink Partnrs, Morgan Stanley, Truist Financial, and Wolfe Research in the past 90 days.
: Analysts like Bristol-Myers Squibb less than other "medical" companies. The consensus rating for Bristol-Myers Squibb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:BMY) was last updated on 1/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target